Sanofi has capitalized on regulatory issues hamstringing Biocon to scoop the first US Food and Drug Administration approval for a biosimilar to Novo Nordisk’s NovoLog (insulin aspart), marking the third insulin biosimilar approved by the agency, and the first rapid-acting insulin biosimilar product.
Sanofi Leapfrogs Biocon To Land First US Rapid-Acting Insulin Biosimilar
French Firm’s Merilog Is First Insulin Approved Since 2021; FDA Eyes Improved Efficiency
Sanofi has bolstered its insulin offerings by bagging the first US FDA approval for a rapid-acting insulin aspart biosimilar, leaving several would-be sponsors in its wake.
More from Biosimilars
More from Business
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).